Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia

Letter to Blood| February 23, 2023 Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia Clinical Trials & Observations Graça M. Dores, Graça M. Dores Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD https://orcid.org/0000-0002-3985-2935 Search for other works by this author on: This Site PubMed Google Scholar Martha S. Linet, Martha S. Linet Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD https://orcid.org/0000-0002-1687-5587 Search for other works by this author on: This Site PubMed Google Scholar Rochelle E. Curtis, Rochelle E. Curtis Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD Search for other works by this author on: This Site PubMed Google Scholar Lindsay M. Morton Lindsay M. Morton Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD https://orcid.org/0000-0001-9767-2310 Search for other works by this author on: This Site PubMed Google Scholar Blood (2023) 141 (8): 951–955. https://doi.org/10.1182/blood.2022018051 Article history Submitted: August 10, 2022 Accepted: November 10, 2022 First Edition: November 15, 2022 Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Request Permissions Cite Icon Cite Search Site Citation Graça M. Dores, Martha S. Linet, Rochelle E. Curtis, Lindsay M. Morton; Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia. Blood 2023; 141 (8): 951–955. doi: https://doi.org/10.1182/blood.2022018051 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBlood Search Subjects: Clinical Trials and Observations, Lymphoid Neoplasia, Myeloid Neoplasia TO THE EDITOR: The risks of therapy-related myelodysplastic syndromes and acute myeloid leukemia (t-MDS/AML) are well-studied1-3; however, few studies have quantified risks of less common therapy-related hematopoietic neoplasms (t-HNs) in chemotherapy-exposed populations. Hindering the assessment of these t-HNs is their rarity, which requires the study of large numbers of patient populations who are at risk. We therefore sought to systematically quantify the risks for several t-HNs, including chronic myeloid leukemia (t-CML), classical myeloproliferative neoplasms (t-cMPNs), chronic myelomonocytic leukemia (t-CMML), and acute lymphoblastic leukemia/lymphoma (tr-ALL) (supplemental Table 1; available on Blood website). We evaluated these t-HNs after a broad spectrum of first primary cancers among adults treated with initial chemotherapy leveraging US population-based cancer registries. In the 17 Surveillance, Epidemiology, and End Results (SEER-17) program areas covering ∼28% of the US population, we identified a cohort of adults (20-84 years)... References 1.Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21(5):897-906.Google ScholarCrossrefSearch ADS 2.Granfeldt Ostgard LS, Medeiros BC, Sengelov H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641-3649.Google ScholarCrossrefSearch ADS 3.Morton LM, Dores GM, Schonfeld SJ, et al. Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA Oncol. 2019;5(3):318-325.Google ScholarCrossrefSearch ADS PubMed 4.Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2018. National Cancer Institute; 2021 https://seer.cancer.gov/csr/1975_2018/.5.Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.Google ScholarCrossrefSearch ADS PubMed 6.Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.Google ScholarCrossrefSearch ADS PubMed 7.Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer. 2002;33(4):331-345.Google ScholarCrossrefSearch ADS PubMed 8.Vardiman JW, Harris NL, Brunning RD. The world health organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.Google ScholarCrossrefSearch ADS PubMed 9.Chen W, Wang E, Lu Y, Gaal KK, Huang Q. Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: report of six cases and a literature review. Am J Clin Pathol. 2010;133(1):75-82.Google ScholarCrossrefSearch ADS PubMed 10.Aldoss I, Stiller T, Tsai NC, et al. Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica. 2018;103(10):1662-1668.Google ScholarCrossrefSearch ADS PubMed 11.Saygin C, Kishtagari A, Cassaday RD, et al. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019;3(24):4228-4237.Google ScholarCrossrefSearch ADS PubMed 12.Furstenau M, Fink AM, Schilhabel A, et al. B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2021;137(16):2267-2271.Google ScholarCrossrefSearch ADS PubMed 13.Aldoss I, Capelletti M, Park J, et al. Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. Leukemia. 2019;33(1):266-270.Google ScholarCrossrefSearch ADS PubMed 14.Tan M, Fong R, Lo M, Young R. Lenalidomide and secondary acute lymphoblastic leukemia: a case series. Hematol Oncol. 2017;35(1):130-134.Google ScholarCrossrefSearch ADS PubMed 15.Sperling AS, Guerra VA, Kennedy JA, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022;140(16):1753-1763.Google ScholarCrossrefSearch ADS PubMed 16.Iriyama N, Tokuhira M, Takaku T, et al. Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML cooperative study group. Leuk Res. 2017;54:55-58.Google ScholarCrossrefSearch ADS PubMed 17.Yang LH, Su P, Luedke C, et al. Chronic myeloid leukemia following treatment for primary neoplasms or other medical conditions. Am J Clin Pathol. 2018;150(3):246-258.Google ScholarCrossrefSearch ADS PubMed 18.Waller CF, Fetscher S, Lange W. Treatment-related chronic myelogenous leukemia. Ann Hematol. 1999;78(8):341-354.Google ScholarCrossrefSearch ADS PubMed 19.Curtis RE, Boice JD, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326(26):1745-1751.Google ScholarCrossrefSearch ADS 20.Nandakumar A, Davis S, Moolgavkar S, Witherspoon RP, Schwartz SM. Myeloid leukaemia following therapy for a first primary cancer. Br J Cancer. 1991;63(5):782-788.Google ScholarCrossrefSearch ADS PubMed 21.Curtis RE, Boice JD, Stovall M, Flannery JT, Moloney WC. Leukemia risk following radiotherapy for breast cancer. J Clin Oncol. 1989;7(1):21-29.Google ScholarCrossrefSearch ADS 22.Subari S, Patnaik M, Alfakara D, et al. Patients with therapy-related CMML have shorter median overall survival than those with de novo CMML: mayo clinic long-term follow-up experience. Clin Lymphoma Myeloma Leuk. 2015;15(9):546-549.Google ScholarCrossrefSearch ADS PubMed 23.Takahashi K, Pemmaraju N, Strati P, et al. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013;122(16):2807-2811. quiz 2920.Google ScholarCrossrefSearch ADS PubMed 24.Dores GM, Curtis RE, Linet MS, Morton LM. Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001-2017. Am J Hematol. 2021;96(12):E451-E454.Google ScholarCrossrefSearch ADS PubMed 25.McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17(9):513-527.Google ScholarCrossrefSearch ADS PubMed © 2023 by The American Society of Hematology2023 © 2023 by The American Society of Hematology2023 You do not currently have access to this content. Sign in via your Institution